Stock ANVS ANNOVIS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-24 pm EDT 		5-day change 1st Jan Change
12.74 USD +7.24% Intraday chart for Annovis Bio, Inc. +41.71% -31.87%
Apr. 01 Annovis Announces Publication That Supports Understanding of Buntanetap?s Mechanism of Action in Humans CI
Mar. 29 Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on Annovis Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ce065df624cddc534a436c08dcb7740d.X-w1Z6WdGxltiI3p3dmSLAqRmqQRrTV_hkBPYGBUUis.a598AZLxSCohzMWKr6HeG1rCwOx68lNNwysLWSYwO1kIqWA07_Z2bSrN6g~21195eb51854276c2094b18a827d4f26

Analyst Recommendations on Annovis Bio, Inc.

Brookline Capital Downgrades Annovis Bio to Hold From Buy, $9 Price Target MT
Canaccord Genuity Initiates Annovis Bio at Buy With $36 Price Target MT
HC Wainwright Cuts Annovis Bio's Price Target to $30 From $40, Keeps Buy Rating MT
Brookline Capital Starts Annovis Bio at Buy With $35 Price Target MT
Annovis Bio, Inc. Receives Positive Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board CI
HC Wainwright Initiates Annovis Bio at Buy With $40 Price Target MT
Ladenburg Thalmann Initiates Annovis Bio at Buy with $37 Price Target MT
Maxim Group Adjusts Annovis Bio Price Target to $26 From $70, Maintains Buy Rating MT
ANNOVIS BIO : Maxim Adjusts Annovis Bio's PT to $45 from $12, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.74 USD
Average target price
35.4 USD
Spread / Average Target
+177.86%
High Price Target
72 USD
Spread / Highest target
+465.15%
Low Price Target
13 USD
Spread / Lowest Target
+2.04%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Annovis Bio, Inc.

Brookline Capital Markets
Canaccord Genuity
HC Wainwright
Ladenburg Thalmann
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ANVS Stock
  4. Consensus Annovis Bio, Inc.